loading
前日終値:
$2.63
開ける:
$2.62
24時間の取引高:
100.87K
Relative Volume:
0.48
時価総額:
$83.99M
収益:
$875.70K
当期純損益:
$-39.57M
株価収益率:
-1.9295
EPS:
-1.3423
ネットキャッシュフロー:
$-33.65M
1週間 パフォーマンス:
-7.17%
1か月 パフォーマンス:
+1.97%
6か月 パフォーマンス:
-15.64%
1年 パフォーマンス:
-50.95%
1日の値動き範囲:
Value
$2.56
$2.69
1週間の範囲:
Value
$2.56
$2.9599
52週間の値動き範囲:
Value
$2.22
$5.74

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
名前
Vistagen Therapeutics Inc
Name
セクター
Healthcare (1166)
Name
電話
650-577-3600
Name
住所
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
職員
0
Name
Twitter
@vistagen
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
VTGN's Discussions on Twitter

VTGN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VTGN
Vistagen Therapeutics Inc
2.59 83.99M 875.70K -39.57M -33.65M -1.3423
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-12-07 アップグレード Jefferies Hold → Buy
2023-08-07 アップグレード Maxim Group Hold → Buy
2022-07-22 ダウングレード Jefferies Buy → Hold
2022-07-22 ダウングレード Robert W. Baird Outperform → Neutral
2022-07-22 ダウングレード William Blair Outperform → Mkt Perform
2021-05-20 開始されました Robert W. Baird Outperform
2021-02-18 開始されました Jefferies Buy
2021-01-04 アップグレード William Blair Mkt Perform → Outperform
2018-06-27 開始されました Maxim Group Buy
2018-02-08 繰り返されました Chardan Capital Markets Buy
2017-03-28 開始されました Maxim Group Buy
すべてを表示

Vistagen Therapeutics Inc (VTGN) 最新ニュース

pulisher
Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025
pulisher
Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR

Mar 21, 2025
pulisher
Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025
pulisher
Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025
pulisher
Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025
pulisher
Mar 12, 2025

Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. - GuruFocus.com

Mar 12, 2025
pulisher
Mar 08, 2025

VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire

Mar 04, 2025
pulisher
Mar 04, 2025

Can Vistagen's Innovative Pherine Technology Disrupt the Neuroscience Market? CEO Presents at Major Forum - StockTitan

Mar 04, 2025
pulisher
Mar 02, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN

Mar 02, 2025
pulisher
Feb 27, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results - accessnewswire.com

Feb 27, 2025
pulisher
Feb 27, 2025

VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat

Feb 25, 2025
pulisher
Feb 20, 2025

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire

Feb 19, 2025
pulisher
Feb 18, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Feb 18, 2025
pulisher
Feb 15, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Feb 15, 2025
pulisher
Feb 14, 2025

VistaGen’s Earnings Call: Progress and Challenges - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication (NASDAQ:VTGN) - Seeking Alpha

Feb 14, 2025
pulisher
Feb 14, 2025

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance

Feb 14, 2025
pulisher
Feb 14, 2025

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlight - GuruFocus.com

Feb 14, 2025
pulisher
Feb 14, 2025

VistaGen Reports Q3 2025 Financial Results and Updates - TipRanks

Feb 14, 2025
pulisher
Feb 13, 2025

Vistagen Reports Q3 Earnings and Pipeline Progress - TipRanks

Feb 13, 2025
pulisher
Feb 13, 2025

Vistagen advances Phase 3 SAD trials with 2025 data readout target - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - sharewise

Feb 13, 2025
pulisher
Feb 13, 2025

Earnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net loss - Investing.com

Feb 13, 2025
pulisher
Feb 13, 2025

Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView

Feb 13, 2025
pulisher
Feb 13, 2025

VistaGen Therapeutics Inc Q3 Loss Increases, But Beats Estimates - Nasdaq

Feb 13, 2025
pulisher
Feb 13, 2025

Vistagen Earnings Reveal $88.6M War Chest, Phase 2A Success Fuels Pipeline Momentum - StockTitan

Feb 13, 2025
pulisher
Feb 12, 2025

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance

Feb 12, 2025
pulisher
Feb 12, 2025

Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result - Yahoo Finance

Feb 12, 2025
pulisher
Feb 07, 2025

Vistagen Therapeutics (VTGN) Projected to Post Earnings on Tuesday - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

USPTO grants patent to Vistagen’s neuropathic pain treatment - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Q3 Earnings Preview: Vistagen to Reveal Latest Progress on Breakthrough Pherine Treatments - StockTitan

Feb 06, 2025
pulisher
Feb 05, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain - sharewise

Feb 05, 2025
pulisher
Feb 05, 2025

Generalized Anxiety Disorder Pipeline 2024: Mechanism - openPR

Feb 05, 2025
pulisher
Feb 05, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain -February 05, 2025 at 08:38 am EST - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Vistagen secures patent for non-opioid pain treatment By Investing.com - Investing.com UK

Feb 05, 2025
pulisher
Feb 05, 2025

Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin - StockTitan

Feb 05, 2025
pulisher
Feb 04, 2025

Short Interest in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Expands By 46.2% - MarketBeat

Feb 04, 2025

Vistagen Therapeutics Inc (VTGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):